| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
ProMIS Neurosciences Inc.
13D/A
PMN · 74346M505
|
17.0% |
2/5/2026
Event 2/3/2026
|
||||
| ABG Management Ltd. | 6.3% | |||||
| Ally Bridge Group (NY) LLC | 6.3% | |||||
| Ally Bridge MedAlpha Master Fund L.P. | 6.3% | |||||
| ABG V-SIV IX Limited | 7.1% | |||||
| Ally Bridge Group Global Life Science Capital Partners V, L.P. | 7.1% | |||||
| ABG Global Life Science Capital Partners V GP, L.P. | 7.1% | |||||
| ABG Global Life Science Capital Partners V GP Limited | 7.1% | |||||
| ABG V-SIV X Limited | 4.5% | |||||
| Fan Yu | 17.0% | |||||
|
ProMIS Neurosciences Inc.
13D/A
PMN · 74346M406
|
11.3% |
2/2/2026
Event 1/29/2026
|
||||
| ABG Management Ltd. | 11.3% | |||||
| Ally Bridge Group (NY) LLC | 11.3% | |||||
| Ally Bridge MedAlpha Master Fund L.P. | 11.3% | |||||
| Fan Yu | 11.3% | |||||
| Schedule 13G · 2 securities · passive | ||||||
|
Whitehawk Therapeutics, Inc.
13G/A
WHWK · 00032Q104
|
9.4% |
8/14/2026
Event 6/30/2026
|
||||
| ABG Management Ltd. | 1.4% | |||||
| Ally Bridge Group (NY) LLC | 1.4% | |||||
| Ally Bridge MedAlpha Master Fund L.P. | 1.4% | |||||
| ABG Innovation Capital Partners III GP Limited | 0% | |||||
| ABG Innovation Capital Partners III GP, L.P. | 0% | |||||
| Ally Bridge Group Innovation Capital Partners III, L.P. | 0% | |||||
| ABG Innovation-SO Limited | 0% | |||||
| ABG Global Life Science Capital Partners V GP Limited | 8.1% | |||||
| ABG Global Life Science Capital Partners V GP, L.P. | 8.1% | |||||
| Ally Bridge Group Global Life Science Capital Partners V, L.P. | 8.1% | |||||
| Abg-Siv, L.P. | 8.1% | |||||
| ABG V-SIV Limited | 8.1% | |||||
| Fan Yu | 9.4% | |||||
|
Ceribell, Inc.
13G/A
CBLL · 15678C102
|
4.6% |
12/11/2025
Event 12/9/2024
|
||||
| ABG WTT-Ceribell Limited | 4.6% | |||||
| ABG V-Ceribell Limited | 4.6% | |||||
| Ally Bridge Group Global Life Science Capital Partners V, L.P. | 4.6% | |||||
| ABG Global Life Science Capital Partners V GP, L.P. | 4.6% | |||||
| ABG Global Life Science Capital Partners V GP Limited | 4.6% | |||||
| Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. | 4.6% | |||||
| ABG-WTT Global Life Science Capital Partners GP, L.P. | 4.6% | |||||
| ABG-WTT Global Life Science Capital Partners GP Limited | 4.6% | |||||
| ABG Management Ltd. | 4.6% | |||||
| Ally Bridge Group (PE) LLC | 4.6% | |||||
| Fan Yu | 4.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.